Author Archives: admin


Stem Cell Clinic > Articles by: admin

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

FARMINGTON HILLS, Mich., April 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan, as a material inducement to Erik Sims in connection with his employment with the Company as Controller of the Company effective on April 1, 2021. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Read more here:
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NKMax America Announces Corporate Name Change to NKGen Biotech

By Global News Feed

SANTA ANA, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that it has changed its corporate name to NKGen Biotech, Inc., which the Company believes best reflects its mission and strategic focus. The name change is effective immediately.

Read the rest here:
NKMax America Announces Corporate Name Change to NKGen Biotech

Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

DUBLIN, Ireland, April 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 106,000 ordinary shares of Nabriva Therapeutics as an inducement to two newly-hired employees. These grants included a non-statutory option to purchase 100,000 ordinary shares of Nabriva Therapeutics awarded to Daniel Dolan, Nabriva’s newly appointed Chief Financial Officer. Both awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation.

See the original post:
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

RESEARCH TRIANGLE PARK, N.C., April 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 46,300 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the new employee’s becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).

View original post here:
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings

By Global News Feed

Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber” or the "Company"), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that its Annual Meeting of Shareholders will be held at 1:00 pm EDT on Thursday, June 3, 2021 (the “Annual Meeting”).  The Company has established April 12, 2021 as the record date for the Annual Meeting.

Read this article:
Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings

ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

By Global News Feed

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) held April 9-11, 2021.

See more here:
ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

→←